重组人血管内皮生成抑制素联合阿法替尼治疗EGFR突变阳性晚期肺腺癌患者的临床效果

目的分析重组人血管内皮生成抑制素联合阿法替尼治疗表皮生长因子受体(EGFR)突变阳性晚期肺腺癌患者的临床效果。方法选取我院2018年6月至2019年1月收治的83例EGFR突变阳性晚期肺腺癌患者,依据治疗方案将其分为试验组(42例)与参照组(41例)。参照组采取阿法替尼治疗,试验组于参照组基础上采取重组人血管内皮生成抑制素治疗。比较两组患者的疗效。结果试验组患者的肿瘤控制率高于参照组(P<0.05);治疗后,两组患者的血清CA199、CA125、CA153、CEA水平均降低,WHOQOL-100评分均升高,且试验组优于参照组(P<0.05)。结论重组人血管内皮生成抑制素联合阿法替尼治疗EGFR突变阳性晚期肺腺癌患者的临床效果确切,能降低肿瘤标志物水平,提升生活质量。

Clinical effect of recombinant human endostatin combined with afatinib in the treatment of EGFR mutation positive patients with advanced lung adenocarcinoma

Objective To analyze the clinical effect of recombinant human endostatin combined with afatinib in the treatment of epidermal growth factor receptor(EGFR) mutation positive patients with advanced lung adenocarcinoma.Methods A total of 83 patients with EGFR mutation positive advanced lung adenocarcinoma admitted in our hospital from June 2018 to January 2019 were selected and divided into experimental group(42 cases) and reference group(41 cases)according to the treatment plan.The reference group was given afatinib,the experimental group was treated with recombinant human endostatin on the basis of the reference group.The curative effects in the two groups were compared.Results The tumor control rate of the experimental group was higher than that of the reference group(P<0.05).After treatment,the levels of serum CA199,CA125,CA153 and CEA in the two groups decreased,the WHOQOL-100 scores increased,and those in the experimental group were better than the reference group(P<0.05).Conclusion Recombinant human endostatin combined with afatinib in the treatment of EGFR mutation positive patients with advanced lung adenocarcinoma has accurate clinical effect,it can reduce the level of tumor markers and improve the quality of life.